QuidelOrtho Appoints Abbott Laboratories Executive as Next CEO

Dow Jones05-02

By Denny Jacob

QuidelOrtho said Thursday that Brian Blaser has been appointed as its next chief executive.

The in-vitro diagnostic technologies provider said Blaser, who was also appointed president, will begin effective May 6. He will also join the board effective May 15.

Blaser most recently served as executive vice president, diagnostic products of Abbott Laboratories.

In February the comapny terminated former CEO Douglas Bryant from his role and formed an office of the chief executive to ensure business continuity. This was led by Chief Commercial Officer Michael Iskra, Chief Operating Officer Robert Bujarski and Chief Financial Officer Joseph Busky. It named Iskra as interim CEO and Bujarski as interim president, in addition to their current roles.

While Blaser's compensation wasn't disclosed, past filings show Bryant earned about $6.8 million in 2023 while Iskra earned about $3.3 million during the same period.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

May 02, 2024 08:41 ET (12:41 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432608028?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-02 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2432608028","market":"fut","top_or_hot":-1,"title":"QuidelOrtho Appoints Abbott Laboratories Executive as Next CEO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  QuidelOrtho  said Thursday that Brian Blaser has been appointed as its next chief executive. \n</p>\n<p>\n  The in-vitro diagnostic technologies provider said Blaser, who was also appointed president, will begin effective May 6. He will also join the board effective May 15. \n</p>\n<p>\n  Blaser most recently served as executive vice president, diagnostic products of Abbott Laboratories. \n</p>\n<p>\n  In February the comapny terminated former CEO Douglas Bryant from his role and formed an office of the chief executive to ensure business continuity. This was led by Chief Commercial Officer Michael Iskra, Chief Operating Officer Robert Bujarski and Chief Financial Officer Joseph Busky. It named Iskra as interim CEO and Bujarski as interim president, in addition to their current roles. \n</p>\n<p>\n  While Blaser's compensation wasn't disclosed, past filings show Bryant earned about $6.8 million in 2023 while Iskra earned about $3.3 million during the same period. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 02, 2024 08:41 ET (12:41 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QuidelOrtho Appoints Abbott Laboratories Executive as Next CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuidelOrtho Appoints Abbott Laboratories Executive as Next CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-02 20:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Denny Jacob \n\n\n \n\n\n  QuidelOrtho  said Thursday that Brian Blaser has been appointed as its next chief executive. \n\n\n  The in-vitro diagnostic technologies provider said Blaser, who was also ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QDEL","symbol_name":"窥得儿医药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2432608028","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432608028","pubTimestamp":1714653660,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"QuidelOrtho  said Thursday that Brian Blaser has been appointed as its next chief executive.The in-vitro diagnostic technologies provider said Blaser, who was also appointed president, will begin effective May 6. He will also join the board effective May 15.Blaser most recently served as executive vice president, diagnostic products of Abbott Laboratories.In February the comapny terminated former CEO Douglas Bryant from his role and formed an office of the chief executive to ensure business continuity. This was led by Chief Commercial Officer Michael Iskra, Chief Operating Officer Robert Bujarski and Chief Financial Officer Joseph Busky. It named Iskra as interim CEO and Bujarski as interim president, in addition to their current roles.While Blaser's compensation wasn't disclosed, past filings show Bryant earned about $6.8 million in 2023 while Iskra earned about $3.3 million during the same period.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QDEL":"窥得儿医药","BK4082":"医疗保健设备","BK4198":"医疗保健用品","ABT":"雅培"},"translate_title":"QuidelOrtho任命雅培公司高管为下一任首席执行官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":1,"QDEL":0.9},"content_text":"By Denny Jacob \n\n\n \n\n\n  QuidelOrtho  said Thursday that Brian Blaser has been appointed as its next chief executive. \n\n\n  The in-vitro diagnostic technologies provider said Blaser, who was also appointed president, will begin effective May 6. He will also join the board effective May 15. \n\n\n  Blaser most recently served as executive vice president, diagnostic products of Abbott Laboratories. \n\n\n  In February the comapny terminated former CEO Douglas Bryant from his role and formed an office of the chief executive to ensure business continuity. This was led by Chief Commercial Officer Michael Iskra, Chief Operating Officer Robert Bujarski and Chief Financial Officer Joseph Busky. It named Iskra as interim CEO and Bujarski as interim president, in addition to their current roles. \n\n\n  While Blaser's compensation wasn't disclosed, past filings show Bryant earned about $6.8 million in 2023 while Iskra earned about $3.3 million during the same period. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 02, 2024 08:41 ET (12:41 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432608028"}